

RESEARCH ADVISORY BOARD (RAB)

October 3, 2017

8:30-10am

Medical Sciences Building, Chancellors Conference Room S-118

Attendees: Wallace Marshall, Michael Nordberg, Elizabeth Sinclair, Eunice Stephens, Vanessa Jacoby, Synthia Mellon, Jennifer Grandis, MC Gaisbauer, Brian Smith, James Sorensen, Suzanne Murphy, Gretchen Kiser, Matthew Springer, Winona Ward

On the phone: John Ellis, Clarice Estrada, David Erle, Jim Kiriakis, Stephanie Louie, David Erle

Not here: Paul Volberding, Jane Czech, Mounira Kenaani, Stephen Lazarus, Georgina Lopez, Teresa Moeller, Christine Razler, Thomas Neylan, Irene McGlynn, Xiao Hu, Feroz Papa, Henry Chambers

Guests/Presenters: Nilo Mia, Jennifer Grandis, Gretchen Kiser

RAB Board Updates

- The Research and Administration Space Policy (RASP) committee conducted a three day kaizan on space and working towards turning ideas into actionale policy. The goal is to identify whether or not space is being utilized appropriately.

Results from the F&A site visit, Nilo Mia

The federal government visited UCSF Mission Bay over a total of three days. Their intent was to identify and walk MB space, interview senior department finance and space staff, and meet with 3 department chairs to discuss academic staffing levels and department space. During their walk they noted vacant, unoccupied, and empty space. The space statistics in terms of how much we identify organized research, clinical care, instruction, etc., space is the main stat for allocating three of the biggest uncapped cost pools in the proposals – building and equipment depreciation, interest costs, operations and maintenance. These cost pools and their space allocation provides the foundation for the F&A rate. If we cannot accurately identify space supporting organized research then we will be unable to maintain the current F&A rate we have or increase it. It became the focus of the review. In this period or cycle of our F&A rate proposal, the F&A team utilized a full-time equivalent (FTE) methodology which is different than our historical room by room inventory. The team evaluated this methodology and implemented an approach which provided result levels that did not deviate significantly from the optimal room by room inventory. Ten departments most from the School of Medicine, were involved in several iterations of questions and responses to the federal government, Departments included Institute of Degenerative Diseases, Neurology, Epidemiology, OBGYN, Radiology, CVRI, Biochem, Pharmchem, Comprehensive Cancer Center, and LARC. They also met with three department chairs which were Brian Black, Jeremy Reiter, and Matt Jacobsen. The buildings that were looked at were the Neuroscience building, Mission Hall, Block 23A, Byers Hall, Cardiovascular, Genentech Hall, Helen Diller, etc. These departments were chosen due to the amount of research space, and high cost of the building. Due to our size and NIH funds, we are a big target for the federal government in regards to F&A rate of reimbursement. UCSF has the highest rate in the UC System at the current level of 58.5% F&A rate. The cost data alone is calculating out to a 69% rate. When future cost projections are added (i.e. 23A, 33A) this adds more points to the F&A rate.

Questions/Comments:

1. How often are audits conducted?
The typical cycle is four years. The last proposal was 2010 (base year) which established our rates until 2016. The latest proposal was 2014 to establish rates for 2017 and beyond.
2. Was UCSF able to secure an increase in F&A rate?
We proposed a higher rate which is subject to review and negotiation. Our current rate is 58.5%. Over the last twenty or so years the rate has slowly increased and is the highest in the UC system.
3. What are the next steps and timeline overall after the audit?
A list of responses is being generated to the federal government and by hopefully by the end of October/early November a new F&A rate will be set.

On-campus funding and limited submission nominee selection, Gretchen Kiser

See Power Point slide attached

Types of on-campus funding:

- Many Intramural Seed-Funding programs manage their funding competitions through the Resource Allocation Program (RAP), for seed grants of \$20,000 - \$100,000.

- The on-campus competition for some philanthropic gift-supported campus research grants, awarding amounts from \$75,000-\$250,000 from a single year to three year period, are managed through the Research Development Office (RDO). Others opportunities on campus including those from QBI, Cancer Center, PBBR, are managed through other offices. The American Cancer Society block grant (through the Cancer Center) is up for review. There are likely many other campus funding options not known to the RDO.
- The Marcus Program has had two cycles offered in April-May. Funds are for bold high-risk high reward projects. Targets are clinical and translational projects based in a basic science question . It is a team science project. Source funding is all gift, which means there has to be substantial management of the donors and managing the competition. Funds range from \$75,000-\$400,000.
- The Weill Institute has also had 2 cycles, with a slightly different different call this year with lower grant amounts. This year it has been a single mechanism, streamlined to make it more straightforward. The award ranges from \$100k-\$200k. Applicants were selected by a nine person panel.
- QBI offers funds this year with an amount of \$225,000 for a two-year project period.
- PBBR is a long-standing program funded by the Sandler family, matched by other gift funds. There are two awards in 2017 and it is meant to fund bold basic science research projects. There are limitations to people who are on certain training grants. There are two different opportunities for awards on campus.
- The Limited Submission Program (LSP) manages the selection of candidates for various limited submission funding opportunities, which are those where only one can be submitted from the entire campus. There is a faculty advisory committee that advises the program and who helps with reviewer selection. These opportunities require very quick turn-arounds but applicants are reviewed by a committee of peers. LSP handles about 110 limited submission opportunities in a year. Notably, there are 30% of opportunities that receive no applicants.

Questions/Comments:

1. How do we loop in all these other programs and encourage people to run their funding competitions through the RAP program?
RAP offers value-add in that faculty are not called in ad-hoc any time of the year to review applications; RAP review is a schedule, 2-cycles per year.

Does RDO plan on doing any outreach?
RAP has always been open to anybody. For many programs there is a perception that they will give up too much program control. We just need to keep spreading the word that RAP allows programs to maintain their control.
2. How does RDO work with the donor and meet their criteria?
A draft call is given to the donor and they review and make comments. The RFA is then reflective of what the donor wants.
3. How many Marcus awards are there?
This 2017 year, seven for \$75k and 3 for \$400k.
4. Is there any tally/listing at the end of the years of people who were awarded and how much?
Currently on the RDO website, all of the awardees for programs managed by RDO are listed under the program. Many of the other program awardees are listed on their websites but some are not listed.

History of Biobanking at UCSF, Dr. Jennifer Grandis

- Biobanking at UCSF was “every person for themselves” which led to an incredibly expensive and uncoordinated program.
- Over 1500 IRB approved Biobanking protocols in 2015.
- Recruited Scott VandenBerg to oversee central biospecimen program and invested in a Laboratory Inventory Management System (LIMS). This is incredibly expensive and no other UC has done this.
- The first five banks will go live in March of 2018.
- What do the investigators at UCSF need in terms of Biospecimens for Research?
- The goal is to set up a virtual biobank, similar to the mouse inventory system so that everybody at UCSF can figure out where to go to get the specimens they need. There are two tiers 1) how do we aggregate the collections that are still very much governed by the individuals who have invested in them? 2) What kind of resources do we need to invest in disease agnostic collections that are not linked to a specific individual/research protocol?
- There is a reasonable recharge mechanism set up to collect biospecimens.

- Much of the progress today has been with the cancer center due to the requirement for a tissue bank in the Cancer Center Support Grant that was recently submitted.
- The cases with annotated tissue biospecimens collected with tissue site SOPs has increased from 74 cases in 2016 to 314 cases in 2017.
- Thought through approach to bring banks such as AIDs, MAC Fluid Bank, CTSI CRS, Cancer Center, Neurodegenerative and Disease Brain Bank.
- Virtual Biobank- a centralized biobanking management system to house and support all UCSF's biological resources.

Questions/Comments:

1. This is all for in-patients?

No, it is for out-patients as well and currently a pilot is going on.

2. How physically would this occur, who would collect it?

This is all part of the program, he has people that go to the location, go to pathology, QA material, process it, and it gets stored in the investigators space. Currently everything being collected is being collected under a specific study. A small pilot was conducted in the Gateway building with an 80% success rate.



University of California
San Francisco

On-campus research funding and limited submission nominee selection

- some highlights

Gretchen L Kiser, PhD

Executive Director, Research Development Office

Research Advisory Board presentation

10/3/2017

Types of on-campus funding

▪ Intramural Seed-Funding

- \$20,000 - \$100,000
- Many managed through RDO's [Resource Allocation Program \(RAP\)](#)
 - Schools and Senate: e.g., REAC, Academic Senate, SoD
 - Large Centers and Center Grants: e.g., CFAR, Center for Tobacco Control Research & Education, Core Center for Musculoskeletal Biology and Medicine (CCMBM)
 - ORUs: e.g., CTSI, Cancer Center, PTBi-CA
- Others offered independently from Schools, Departments, Divisions, and Centers.

Types of on-campus funding

▪ Campus Research Grants

- \$75,000 - \$250,000
- Source funding varies
- Managed by several different offices
 - RDO – large donor gifts: UCSF-Weill Institute, Marcus Awards
 - QBI – Bold and Basic Grants and Fellowships
 - Cancer Center – ACS, Cancer Center Impact Grant
 - PBBR – Program for Breakthrough Biomedical Research

Marcus Program in Prec. Med. Innovation

- [MPPMI](#) fosters high risk, high impact team science projects anchored in basic science and extending into the precision medicine continuum toward improved patient outcomes
- 2-page proposal – panel review and selection of awardees
- Source funding: Joan and Sanford I. Weill gift
- Competition and award managed by RDO
- **Marcus Program Seeding Bold Ideas Award (MP-SBI)**
 - Up to \$75,000 for one year
 - SBI awards enable initial exploration of untested concepts or hypotheses with great potential impact
- **Marcus Program Transformative Integrated Research Award (MP-TIR)**
 - Up to \$400,000 for one year; eligible to compete for up to \$400,000 in year two, if funds are available
 - TIR awards support new directions for established basic science-driven translational studies

Weill Institute for Neurosciences

▪ 2017 Trailblazer Award

- \$100,000 (total costs) for a single investigator project or up to \$200,000 (total costs) for a multiple PI proposal**; single year projects
- Researchers with UCSF faculty appointments
- to fund compelling, high risk/high reward research in the neurosciences; focused on a broad spectrum of neuroscience challenges, including therapeutics, diagnostics, imaging technology, biomarker discovery/validation, and computational methods.
- Source funding: Joan and Sanford I. Weill gift
- 3-page proposal – 3 review panels (by project topic) selection of finalists – Executive Committee selection of awardees
- Competition and award managed by RDO

** - note: all project budgets reduced by 25%

Quantitative Biosciences Institute (QBI)

- **QBI Bold and Basic Grant**

- \$225,000; two year project period; open to all trainees and faculty
- psychiatric/neuroscience research and two to cancer research
- Supporting bold studies involving both basic and clinical research, addressing key problems in psychiatry/neuroscience or cancer that would be unlikely to be supported through conventional grants
- Source funding: Department of Psychiatry, the Cancer Center, and the Quantitative Biosciences Consortium (QBC)
- 2-page proposal – panel selection of finalists – 10min live-pitch – panel selection of 4 awardees

- **QBI Bold and Basic Fellowship**

- \$50,000; open to trainees
- 1-page proposal – panel selection of awardees

Helen Diller Family Comprehensive Cancer Center (Cancer Center)

- Cancer Center Impact Award

- \$250,000; two year project period; open to all trainees, faculty, and staff scientists
- fund one high-risk, high-reward research project – novel, impactful studies to address a key problem in cancer that would be unlikely to be supported through conventional mechanisms
- Anonymous 2-page proposal – panel selection of finalists – 5 min live-pitch – anonymous panel selection of 4 awardees

- American Cancer Society (ASC) Institutional Research Grants

- UCSF currently in-review
- \$90,000 per year for three years given to institutions as "seed money" for the initiation of projects by promising junior investigators

Program for Breakthrough Biomedical Research (PBBR)

▪ New Frontier Research (NFR) Award

- \$25,000 to \$150,000 for one year
- Supports basic science research projects at levels of risk and innovation substantially exceeding levels supported by NIH.
- Multiple awards issued; two cycles/year
- Source funding: Share between Sandler gift and campus
- 2-page proposal – panel selection of awardees

▪ Technologies, Methodologies, and Cores (TMC)

- *\$50,000 to \$500,000 for one year in matching funds*
- Multiple awards issued; one cycle per year
- Awards can be made to both single-PI and multiple-PI projects
- Source funding: Share between Sandler gift and campus
- 2-page proposal – panel selection of awardees

Limited Submission Program (LSP)

- LSP manages the selection of candidates for various limited submission funding opportunities
 - “Prestigious” foundation awards: e.g., Keck, Rita Allen, Pew, Mallinkrodt, Damon Runyon, Packard, V Foundation, St. Baldrick’s, Hyundai, Hellman Fellows, Pew-Stewart, Searle, Blavatnik
 - For NIH and NSF equipment funding grants, RRP coordinates with LSP
 - Closely partner with RMS – communicate nominee name(s)
 - Closely partner with UCSF Corporate and Foundation Relations in hand-off of nominees for funders in their portfolio
- Handles ~110 limited submission opportunities per year, where about a third requires a full review committee, and a third receives no applications
- Where there is more than one applicant, ad hoc committees are formed: 3-9 reviewers (often with a previous recipient), ~ up to 15 applicants per opportunity
- In order to give selected nominee the most time to prepare their actual submission, the selection process is designed for a quick turn-around. If under 30-days until funder deadline, nominee is the first in

Help us, help you...

Limited Submission Listserv: subscribe to receive timely announcements of all limited submission opportunities and stay informed of any relevant internal competitions [Sign up for Limited Submissions Emails](#)

Funding Opps Listserv: subscribe to receive announcements of funding opportunities of broad interest to faculty or from unusual funders [Sign up for Funding Opps Emails](#)

Pivot: an online searchable database of global funding opportunities – set up a custom search within Pivot to push funding announcements to your email on a regular basis [Set-up a Pivot search](#)

There's a wealth of information and help in the RDO, so please avail yourself and your research to the [great team of RDO professionals](#).

http://pivot.cos.com/funding_main



pivot University of California, San Francisco

[Log in](#)

[About COS Pivot](#)



Funding

Profiles

Funding



Create your Pivot Account

You must be affiliated with an institution that subscribes to Pivot in order to create an account. You will receive a verification email. Once your account is created, your email address will be your Pivot user id.

All fields required.

Name

Email

Password

Re-enter password

Affiliated Member Institution



Create my account

[Support/Help](#) | [About Pivot](#) | [Privacy](#) | [Terms of Use](#) | [Contact](#)

© 2013, ProQuest, LLC. All rights reserved.



“Opportunity is missed by most people because it is dressed in overalls and looks like work.” – Thomas Edison

Questions? Contact Gretchen Kiser:
gretchen.kiser@ucsf.edu or
rdoinfo@ucsf.edu



University of California
San Francisco

History of Biobanking at UCSF

- Decentralized
- Uncoordinated
- Expensive for groups to set up and maintain tissue collections
- >1500 IRB approved biobanking protocols in 2015
- Institutional investment in 2015: strategic resources, Scott VandenBerg recruitment, LIMS, BIOS
- Progress to date
- What do investigators need from BIOS?

UCSF Biospecimen Resources (BIOS) Program

Three Programmatic Areas... for allocation of capital resources



Acquisition of
Biospecimens



Processing &
Quality Control



Software
Implementation

- Develop infrastructure to increase the number of high-quality, well-annotated human biospecimens to support translational research and precision medicine at UCSF.
- Facilitate synergy of existing biobanks and research biospecimen handling across the campus community without interfering with disease-group governance of biospecimens.
- To implement an enterprise-wide software platform for biospecimen lifecycle annotation and management.
- Develop an efficient pipeline for excess clinical specimens research.

Biobanking Needs at UCSF

- Coordinate/support existing biobanks
- Support new biobanks
- Catalogue UCSF collections to drive collaborations (“matchmaker”)
- Central collection to support investigators/collaborations

BIOS WEBSITE

UCSF University of California San Francisco

About UCSF Search UCSF UCSF Medical Center

Search...

Biospecimen Resources (BIOS) Program

Home For Researchers For Patients About Us

UCSF BIOS Program



High-quality biospecimens are a cornerstone of the world-class biomedical research being achieved at UC San Francisco and are essential for precision medicine, a key priority for UCSF. The mission of the UCSF Biospecimen Resources (BIOS) Program is to support excellence in biobanking activities and provide high-quality human biospecimens and data for research.

The BIOS Program facilitates the development of precision medicine by increasing the number, quality, and value of specimens available for research at UCSF. It works across the campus to strengthen and coordinate UCSF's biobanking activities and provides a suite of biospecimen-related services and infrastructure to UCSF investigators.

Our Focus Areas

- Biospecimen Acquisition
- Biospecimen Processing & Quality Control
- Biospecimen Management Software

UCSF INVESTIGATORS: Connect with BIOS

- Request BIOS Services
- Recharge Rates
- For Questions or Consultation

Subscribe to BIOS Mailing List

Email Address * (Indicates required)
First Name
Last Name
Subscribe

Biospecimen Resources (BIOS) Program

Home For Researchers For Patients About Us

Home > For Researchers

For Researchers

The BIOS Program is a comprehensive solution for UCSF investigators seeking assistance with biospecimens. We provide tools and services that make acquiring, processing, annotating and managing biospecimens more efficient, less costly and less time consuming.

Our focus is on building a world-class, scalable biorepository infrastructure at UCOF, not on governing disease-group biobanks. As such, our work is centered on increasing the number of high-quality biospecimens and developing biospecimen management resources that spur new research projects and collaborations.

Explore & Access Services



Biospecimen Acquisition Biospecimen Processing & Quality Control



Biospecimen Management Software Other Resources

FOR RESEARCHERS:

- Biospecimen Acquisition
- Biospecimen Processing & Quality Control
- Biospecimen Management Software
- Other Resources

UCSF INVESTIGATORS: Connect with BIOS

- Request BIOS Services
- Recharge Rates
- For Questions or Consultation

Subscribe to BIOS Mailing List


Email Address * (Indicates required)
First Name
Last Name
Subscribe

Biospecimen Resources (BIOS) Program

Home > For Patients

For Patients

Biospecimens are important because they allow researchers to better understand the causes of diseases and evaluate potential therapies. Patients can partner with UCSF to advance research by donating their leftover specimens following clinical tests or agreeing to donate a specimen following a procedure. Ask medical staff how to participate.



Donating your biospecimens is a generous act that contributes to a healthier future for everyone!



What are Human Biospecimens?



What are Research Biorepositories?

Biospecimen Resources (BIOS) Program

Home > About Us > Our Team

About Us



Our Team



Scott Vandenberg, MD, PhD
Director of UCSF BIOS Program
Director of Biorepository and Tissue Biomarker Technology Core, HFDCC
Email: BIOS@ucsf.edu



Tasha Lea, MS, PA ASCP
Senior Pathologist's Assistant
Email: Tasha.Lea@ucsf.edu



Helene Bour-Jordan, PhD
Program Manager
Email: Helene.Jordan@ucsf.edu



Nicola Gabancho
Functional Lead
Email: Nicola.Gabancho@ucsf.edu



David Aaronson
Project & Operations Manager
Email: David.Aaronson@ucsf.edu



Vincent Te
Systems Engineer
Email: Vincent.Te@ucsf.edu



Sudeep Basnet, MS
Executive Technical Lead
Email: Sudeep.Basnet@ucsf.edu



Candice Pyun
Project Analyst
Email: Candice.Pyun@ucsf.edu

PROSPECTIVE UCSF BIOSPECIMEN COLLECTION

The Specialist Acquisition Team was first deployed in 2016 for three tumor groups

Breast Oncology

Colon/Liver

Head/Neck Tumors

IPI-Immunoprofiler Group

Currently the Tumor Groups/Programs that are now or will be fully implemented with the Acquisition Team are -

Adult Soft Tissue & Bone Tumors,

Breast Oncology

Cancer Immunotherapy / IPI Programs

Head & Neck Tumors,

GU tumors (Q3-4/2017)

GI-Colorectal

GI- Hepatobiliary (tumor)

GI-Pancreas, Gyn-On


Liver Transplant

Liver Center (cancer/non-cancer projects)

Solid Pediatric Tumors (including sarcoma)

SIGNIFICANT PROGRESS FOR ANNOTATED TISSUE ACQUISITION

Tissue Acquisition by Specialist Team





ORGAN/TISSUE SITE or DISEASE GROUP

Organ/Tissue Site Disease Group	Cases with Matched Blood
Head and Neck	36%
Colon	44%
Liver	90%
Breast	0%
Transplant	100%
Sarcoma	25%
Ovary and Uterus	68%


FLUID- ONLY SPECIMENS PROCESSED BY THE BIOS-HDFCCC BIOREPOSITORY

CURRENT CLINICAL TRIAL FLUID BIOSPECIMENS MANAGED BY BIOS- HDFCCC BIOREPOSITORY 2016 Q4 - 2017 Q2	32 protocols 6 disease sites
blood tubes plasma processed	1203
blood tubes serum processed	530
DNA PAX tube processed	27
cf DNA (Streck BCT tube)processed	55
RNA PAX tube processed	115
CPT tubes processed	256
plasma aliquots	stored 278
	shipped 1335
serum aliquots	stored 68
	shipped 1034
whole blood	stored 5
	shipped 848
buffy coat DMSO	stored 122
	shipped 3
buffy coat	stored 49
	shipped 102
urine processed	stored 72
blood smear slides shipped	156
patients processed (total 537 pt visits)	147


Quality Control Workflows for Tissue Biospecimens



FFPE QA Blocks Stained with H&E and Imaged by Whole Slide Scanning



Extension of Tissue QA/QC Modalities is Translational Biomarker Technology



Including State-of-the-Art Image Analysis

- **Facilitate synergy of existing biobanks and research biospecimen handling across the campus community without interfering with disease-group governance of biospecimens.**

SIGNIFICANT PROGRESS HAS BEEN MADE FOR PROVIDING SINGLE INFRASTRUCTURE FOR MULTIPLE BANKS

Biospecimen Banks Managed by the BIOS-HDFCCC Biospecimen Repository															BY 2017 Q3	Totals
		Hepatobiliary Tissue Bank and Registry (CC 124512)	Oral, Head and Neck Surgical Oncology Tissue Bank (CC15205)	Colorectal Arm of Molecular Profiling in Gastrointestinal Malignancies (CC134510)	Pancreas Arm of Molecular Profiling in Gastrointestinal Malignancies (CC134510)	Pancreas Bank (De-identified)	Pancreas CAPTURE (CC 114510)	Molecular Profiling in Thoracic Malignancies (CC136512)	Canary Prostate Active Surveillance Study (PASS)	ATHENA (Breast Oncology Group)	Proteomics (Breast Oncology Group)	Cancer Risk	Prostate Surgical Oncology Bank (CC90991)	Kidney Surgical Oncology Bank (CC02542)	Bladder Surgical Oncology Bank (CC90992)	
Patients	Patients with Tissue Collected	57	60	21	21	386	48	68	193	0	871	6641	3196	937	806	13305
	Patients with Blood (&/or Saliva, other BF) Collected	260	16	14	25	0	50	139	221	3755	871	0	3522	1575	814	11262
	Patients with Urine												2039	426	406	2871
	Patients with Matched Tissue and Blood (&/or Saliva &/or Urine)	37	16	13	11	0	43	63	193	0	871	6641	2870*	840*	722*	7888
Tissue	Snap Frozen Vials	18	47	45	6	0	0	2	0	0	0	0	0	0	0	118
	OCT Molds	282	63	4	4	769	90	66	810	0	0	0	9996	3738	2100	17922
	FFPE Blocks	26	57	44	37	56	0	0	79	0	0	0	0	0	0	299
	Viable Freeze or Culture Media	12	39	32	21	0	0	0	0	0	0	0	0	0	0	104
Blood and Body Fluids	Whole Blood Aliquots	2110	32	28	155	0	221	668	0	8379	0	4986	5399	781	1568	24327
	Serum Aliquots	1978	80	0	27	0	467	966	9385	29939	8710	0	15001	816	3606	70975
	Plasma Aliquots	1909	82	52	132	0	460	993	23039	30171	6968	36857	16590	976	3796	122025
	Viable Cell Freeze Aliquots	4	0	0	0	0	0	0	903	0	2353	0	2404	1092	516	7272
	Buffy Coat Aliquots	627	32	30	47	0	100	336	445	5865	0	12960	562	172	213	21389
	Saliva	0	0	0	0	0	0	0	0	1037	0	0	0	0	0	1037
	Urine Aliquots	0	0	0	0	0	0	0	6148	0	0	0	2039	426	406	9019
Distribution	Tissue Aliquot Distributions	48	39	44	21	38	16	10	193	0	0	0	964	324	94	1791
	Blood (and or Saliva) Aliquot Distributions	112	7	11	9	0	0	75	20547	1574	50	919	592	25	26	23947
	Urine Aliquot Distributions	0	0	0	0	0	0	0	5916	0	0	0	77	0	12	6005


LONG-TERM SOLUTION FOR BIOSPECIMEN LIFE CYCLE ANNOTATION AND MANAGEMENT

LabVantage Software Platform for Biospecimens

- Patient Consent Tracking
- Study Management
- Collection Kit Management
- Biospecimen Collection SOPs and Annotation
- Biospecimen Genealogy
- Searchable Inventory Management
- Chain of Custody
- Requests and Distributions
- Biospecimen Clinical Annotation/Health System Links
- Biospecimen Research Data/Data Warehouse Links
- Data Security and Compliance

A thorough RFP was conducted with broad campus involvement & selection of LabVantage as the enterprise solution in December 2015

Implementation Strategy



BIOS ACTIVITIES FOR FUTURE DEVELOPMENT

- Expansion of Acquisition Team Activities to all OR/Clinic (including FNA) Research Tissue Acquisition
- Enterprise-Wide Clinical Remnant and Research Blood Collection Pipeline with eConsenting Modality
- Campus-Wide Storage Strategies and Buildout
 - Dry Membrane Storage Core
 - Liquid Nitrogen -80C Freezers
 - Scalable Liquid Nitrogen Vapor Storage
- Progressive Implementation of LABVantage for Existing Biobanks
- Virtual Biobank Software Platform

UCSF Virtual Biobank – the possibilities

- Deliverables
 - A centralized biobanking management system to house and support all UCSF's biological resources
 - UCSF could reference our current mouse inventory database
- Features
 - Allow researchers to browse / search the database through a number of data points including:
 - Sample type, site location & method of collection
 - Patient demographics including: gender, diagnosis
 - Disease type
 - Working groups to match & coordinate clinicians, researchers and clinician researchers

UCSF Virtual Biobank – the possibilities, cont.

- Regulation & decision making
 - Governance committee to oversee all activity/ processes
 - Independent from home department
- Benefits
 - Provides tracking of all samples, including chain of custody
 - Creates an audit trail
 - Supports research with readily available data that would otherwise be lost

UCSF Mouse Database: <https://mousedatabase.ucsf.edu>

UCSF Mouse Inventory Database

[Home](#) [Submit Feedback](#)

[Search](#) [Mouse Records](#) [Gene List](#) [Holder List](#) [Facility List](#) [Submit Mice](#)

Quick Search

Admin use only

Welcome to the UCSF Mouse Inventory Database

This database provides a central online resource that describes mice currently housed at UCSF.

Users can go online with a web browser to determine if mice carrying a particular genetic alteration or mice of a particular inbred strain are available in the colony of one or more investigators at the university and to find out whom to contact about the possibility of obtaining the mice. Access to this information should save investigators considerable time and money in acquiring mice, as well as stimulate collaboration between investigators.

In addition, for each investigator listed as a 'holder' in the database, a description of all the mice in his/her colony can be readily obtained.

I would like to...



Search for mice



Submit a new mouse



Learn about the database

Need help using the database?

[DOWNLOAD USER'S MANUAL \(pdf\)](#)

REQUEST A DEMONSTRATION

Contact Estelle Wall
admin.mousedatabase@ucsf.edu

ASK A NEIGHBOR

A number of people have volunteered to provide their neighbors with assistance in navigating the database, submitting change requests and entering new mice.

To find the name of someone in your neighborhood who can help you with database questions, go to the [Facilities List](#).

Obtain a powerpoint presentation in which mutant alleles and transgenes are explained.

[DOWNLOAD 'READ ME FIRST! MOUSE MUTANTS: A PRIMER' \(ppt\)](#)

Obtain a powerpoint presentation that describes how to use tools available on the internet to find mouse mutants for your gene of interest.

[DOWNLOAD 'HAVE GENE, WANT MOUSE' \(ppt\)](#)